Format

Send to

Choose Destination
Haematologica. 2018 Nov;103(11):e541-e543. doi: 10.3324/haematol.2018.194399. Epub 2018 May 24.

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Author information

1
Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
2
Biotech Research and Innovation Centre, Copenhagen, Denmark.
3
Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Oncology and Pathology, Sweden.
4
Department of Oncology, Oslo University Hospital, Norway.
5
Department of Oncology, Uppsala University Hospital, Sweden.
6
Department of Hematology, Helsinki University Hospital, Finland.
7
Department of Hematology, Rigshospitalet, Copenhagen, Denmark kirsten.groenbaek@regionh.dk.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center